Sublimity Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Sublimity Therapeutics Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10528
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アイルランド
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Sublimity Therapeutics Ltd(Sublimity) formerly known as Sigmoid Pharma Ltd, focuses on the development of therapeutics for unmet clinical needs in gastrointestinal and immunological diseases and disorders. The company’s product portfolio includes cyclosporine, oral vaccines, oral peptides and formulations. Sublimity develops therapies by using its proprietary technology, SmPill (single-multiple pill) for the treatment of crohn’s disease, graft versus host disease, psoriasis, diarrhoea, helicobacter pylori, colon cancer, coeliac disease and inflammatory bowel. It works in collaboration with the Advanced Immunization Technologies Consortium, Irish Drug Delivery Network and TRANSINT Consortium among others. The company operates GMP manufacturing facility in the Invent Centre. Sublimity is headquartered in Dublin, Ireland.

Sublimity Therapeutics Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Sublimity Therapeutics Raises USD64 Million in Venture Financing 10
Sigmoid Pharma Raises US$3.8 Million In Venture Financing 12
Licensing Agreements 13
Dr. Falk Pharma Enters into Licensing Agreement with Sigmoid Pharma 13
Sigmoid Pharma Enters into Licensing Agreement with PendoPharm for CyCol 14
Equity Offering 15
Sigmoid Pharma Raises USD6.3 Million in Private Placement 15
Acquisition 16
Sigmoid Pharma Acquires Freund Pharmatec 16
Sublimity Therapeutics Ltd – Key Competitors 17
Sublimity Therapeutics Ltd – Key Employees 18
Sublimity Therapeutics Ltd – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
Mar 06, 2017: Sigmoid Pharma Announces the Appointment of Lorin K. Johnson, PhD as a Non-Executive Director 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sublimity Therapeutics Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Sublimity Therapeutics Raises USD64 Million in Venture Financing 10
Sigmoid Pharma Raises US$3.8 Million In Venture Financing 12
Dr. Falk Pharma Enters into Licensing Agreement with Sigmoid Pharma 13
Sigmoid Pharma Enters into Licensing Agreement with PendoPharm for CyCol 14
Sigmoid Pharma Raises USD6.3 Million in Private Placement 15
Sigmoid Pharma Acquires Freund Pharmatec 16
Sublimity Therapeutics Ltd, Key Competitors 17
Sublimity Therapeutics Ltd, Key Employees 18
Sublimity Therapeutics Ltd, Subsidiaries 19

List of Figures
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Sublimity Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Sublimity Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • J D Wetherspoon plc:企業の戦略・SWOT・財務分析
    J D Wetherspoon plc - Strategy, SWOT and Corporate Finance Report Summary J D Wetherspoon plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • gategroup Holding AG:企業の戦略・SWOT・財務情報
    gategroup Holding AG - Strategy, SWOT and Corporate Finance Report Summary gategroup Holding AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Inchcape plc (INCH):企業の財務・戦略的SWOT分析
    Inchcape plc (INCH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Central Alabama Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Central Alabama Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • PostNL NV (PNL):企業の財務・戦略的SWOT分析
    PostNL NV (PNL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • BWP Trust:企業の戦略・SWOT・財務情報
    BWP Trust - Strategy, SWOT and Corporate Finance Report Summary BWP Trust - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Beach Energy Ltd (BPT):企業の財務・戦略的SWOT分析
    Beach Energy Ltd (BPT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Jiuzhitang Co Ltd (000989):製薬・医療:M&Aディール及び事業提携情報
    Summary Jiuzhitang Co Ltd (Jiuzhitang), formerly Labor Jiuzhitang Pharmacy, is a Chinese medicine manufacturing company. The company offers products such as shuxuetong injection, lujiao granule, liuwei dihuang wan pills, zuguang power, siqikang injection, luo hua zi zhu tablets, compound jiangzhi ta …
  • Hays plc:企業の戦略・SWOT・財務情報
    Hays plc - Strategy, SWOT and Corporate Finance Report Summary Hays plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Cedar Fair, L.P.:企業の戦略・SWOT・財務情報
    Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report Summary Cedar Fair, L.P. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Traverse Energy Ltd (TVL):石油・ガス:M&Aディール及び事業提携情報
    Summary Traverse Energy Ltd (Traverse Energy), formerly Firstland Energy Ltd is an oil and gas company that explores, produces, and develops petroleum and natural gas assets. The company's products include crude oil, natural gas, petroleum products, and associated liquids, among others. It explores …
  • Aldermore Bank Plc:企業の戦略・SWOT・財務分析
    Aldermore Bank Plc - Strategy, SWOT and Corporate Finance Report Summary Aldermore Bank Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • GE Healthcare LLC-製薬・医療分野:企業M&A・提携分析
    Summary GE Healthcare LLC (GE Healthcare) a business unit of General Electric Company, is a global medical device provider that designs, develops, manufactures, and distributes diagnostic imaging and clinical systems; products and services for drug discovery, biopharmaceutical manufacturing and cell …
  • Nutra Pharma Corp (NPHC):企業の財務・戦略的SWOT分析
    Nutra Pharma Corp (NPHC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Westar Energy Inc (WR):企業の財務・戦略的SWOT分析
    Westar Energy Inc (WR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Delphi Energy Corp (DEE):企業の財務・戦略的SWOT分析
    Delphi Energy Corp (DEE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • MSM Malaysia Holdings Berhad (MSM):企業の財務・戦略的SWOT分析
    MSM Malaysia Holdings Berhad (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Enable Midstream Partners LP (ENBL):石油・ガス:M&Aディール及び事業提携情報
    Summary Enable Midstream Partners, LP (Enable), a subsidiary of CenterPoint Energy Inc, owns, operates, and develops natural gas and crude oil infrastructure assets. It is a limited partnership among CenterPoint Energy, OGE Energy and ArcLight Capital Partners, LLC. The company offers crude oil and …
  • Dexus Property Group:企業のM&A・事業提携・投資動向
    Dexus Property Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dexus Property Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Idorsia Pharmaceutical Ltd (IDIA):製薬・医療:M&Aディール及び事業提携情報
    Summary Idorsia Pharmaceutical Ltd (Idorsia) is a manufacturer and developer of medicine that discovers, develops various therapies. The company provides pipeline portfolio such as investigational candidates targeted at the treatment of resistant hypertension, chronic insomnia, vasospasm, and system …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆